UNSPSC 51152024: Dantrolene sodium

This classification denotes a muscle relaxant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 287M0347EV. European Medicines Agency schedules Dantrolene sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01553MIG. Dantrolene sodium generally arises in the molecular formula C14H9N4NAO5. The term DANTROLENE SODIUM is a United States Adopted Name designation. Most nations schedule dantrolene sodium under HS 29349990 and SITC 51579.

As of Q4 2014, DANTROLENE SODIUM remains the US FDA Preferred Term for this commodity. Dantrolene sodium bears US NLM identifiers UMLS ID C0010977 and NCI Concept Code C61698. SMILES: C1C(=O)N=C(N1N=CC2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-])[O-].[NA+].

UNSPSC 51152024 Dantrolene sodium is a Commodity code that in recent state and local procurement shows little activity directly matching the code's pharmaceutical scope. The single relevant opportunity on record is Seminole County, Florida's IFB for naloxone and drug deactivation systems (IFB60459723LAS, posted June 30, 2026, due July 26, 2023), which procures injectable emergency medications and harm-reduction equipment rather than dantrolene specifically. The second recent record—a Texas Health and Human Services Commission RFI on direct-to-manufacturer prescription programs—represents exploratory market intelligence gathering on pharmacy benefit structure and does not solicit dantrolene or any named pharmaceutical product. State and local solicitations under this code appear sparse and do not yet reflect consistent demand for dantrolene as a standalone procurement item.

Seminole County's naloxone bid represents the strongest signal of pharmaceutical procurement activity in the recent dataset and involved a competitive bidding process with annual volume (1,900 units of naloxone, 800 drug deactivation systems), quarterly delivery to a named health facility, and standard compliance requirements including drug-free workplace certification and E-Verify. The Texas RFI signals emerging state-level interest in reshaping pharmacy procurement relationships but remains in information-gathering phase with no award value or formal competitive timeline. Geographic activity is concentrated in Florida and Texas, though the Texas initiative has not yet advanced to formal solicitation. Firms evaluating dantrolene opportunities in state and local markets should monitor Florida health departments and Texas HHS further procurement for any future pharmaceutical purchasing activity, but current volume and frequency under this code do not yet support sustained pursuit.